...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pakistan journal of medical sciences. >Therapeutic effects of mifepristone combined withGestrinone on patients with endometriosis
【24h】

Therapeutic effects of mifepristone combined withGestrinone on patients with endometriosis

机译：米非司酮联合孕酮对子宫内膜异位症的治疗作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To evaluate the clinical therapeutic effects of mifepristone combined with gestrinone on patients with endometriosis.Methods: A total of 150 endometriotic patients treated in our hospital between January 2014 and December 2015 were randomly divided into a control group and a treatment group (n=75). The control group began to orally take gestrinone capsules on the second day after menstruation started (2.5 mg/time, twice/week). The treatment group orally took mifepristone tablets (12.5 mg/time, once/day), and the dosage and administration of gestrinone capsules were the same as those of the control group. After 24 weeks of consecutive treatment, the clinical therapeutic effects of the two groups were assessed, and the pelvic symptom score, clinical sign score, serum sex hormone levels and pregnancy outcomes were compared.Results: The total effective rates of control and treatment groups were 77.3% and 90.7% respectively, between which the difference was statistically significant (P<0.05). After treatment, the scores of pelvic symptoms (dysmenorrhea, dyspareunia, pelvic pain) and clinical signs (pelvic tenderness, induration) significantly reduced (P<0.05). Each score of the treatment group decreased more significantly than that of the control group did (P<0.05). The serum follicle hormone, luteinizing hormone, estrogen and progesterone levels were significantly lower than those before treatment (P<0.05). Each level of the treatment group dropped more significantly than that of the control group did (P<0.05). The pregnancy rates in the 6th and 12th months of follow-up were 28.0% and 13.3% in the control group respectively, and 42.7% and 29.3% in the treatment group respectively. Such rates of the two groups were significantly different at each follow-up time point (P<0.05).Conclusion: Mifepristone combined with gestrinone had satisfactory clinical therapeutic effects on endometriosis by reducing hormone levels and improving pregnancy outcomes. Therefore, this regimen is worthy of promotion and application in clinical practice.doi: http://dx.doi.org/10.12669/pjms.325.10772How to cite this:Xue HL, Yu N, Wang J, Hao WJ, Li Y, Liu MY. Therapeutic effects of mifepristone combined with Gestrinone on patients with endometriosis. Pak J Med Sci. 2016;32(5):1268-1272. doi: http://dx.doi.org/10.12669/pjms.325.10772This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
机译：目的：评价米非司酮联合孕酮对子宫内膜异位症的临床疗效。方法：将我院2014年1月至2015年12月收治的150例子宫内膜异位患者随机分为对照组和治疗组。 75）。对照组在月经开始后第二天开始口服孕酮胶囊（2.5 mg /次，每周两次）。治疗组口服米非司酮片（12.5 mg /次，一次/天），孕酮胶囊的剂量和给药方法与对照组相同。连续治疗24周后，评估两组的临床疗效，并比较盆腔症状评分，临床体征评分，血清性激素水平和妊娠结局。结果：对照组和治疗组总有效率分别为77.3％和90.7％，两者之间的差异具有统计学意义（P <0.05）。治疗后，骨盆症状（痛经，痛经，骨盆疼痛）和临床体征（骨盆压痛，硬结）的评分显着降低（P <0.05）。治疗组各项得分的下降幅度均明显高于对照组（P <0.05）。血清卵泡激素，黄体生成素，雌激素和孕激素水平明显低于治疗前（P <0.05）。与对照组相比，治疗组各水平下降幅度更大（P <0.05）。随访第6个月和第12个月的妊娠率，对照组分别为28.0％和13.3％，治疗组分别为42.7％和29.3％。结论：米非司酮联合孕酮对子宫内膜异位症具有良好的临床治疗作用，可通过降低激素水平和改善妊娠结局而达到满意的临床治疗效果（P <0.05）。因此，该方案值得在临床实践中推广和应用。doi：http://dx.doi.org/10.12669/pjms.325.10772如何引用这一点：薛HL，于N，王J，郝WJ，李Y刘敏米非司酮联合孕酮对子宫内膜异位症的治疗作用。朴J医学。 2016; 32（5）：1268-1272。 doi：http://dx.doi.org/10.12669/pjms.325.10772这是根据知识共享署名许可（http://creativecommons.org/licenses/by/3.0）的条款分发的开放访问文章，只要适当引用了原始作品，便可以在任何介质中不受限制地使用，分发和复制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号